Impel NeuroPharma (NASDAQ:IMPL – Get Rating) is one of 937 public companies in the “Pharmaceutical preparations” industry, but how does it compare to its rivals? We will compare Impel NeuroPharma to related companies based on the strength of its profitability, analyst recommendations, institutional ownership, valuation, risk, dividends and earnings.
This is a breakdown of current recommendations for Impel NeuroPharma and its rivals, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Impel NeuroPharma Competitors||6122||20670||43014||858||2.55|
Insider & Institutional Ownership
78.5% of Impel NeuroPharma shares are held by institutional investors. Comparatively, 45.4% of shares of all “Pharmaceutical preparations” companies are held by institutional investors. 14.7% of shares of all “Pharmaceutical preparations” companies are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
This table compares Impel NeuroPharma and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Impel NeuroPharma Competitors||-4,343.45%||-115.55%||-11.42%|
Earnings and Valuation
This table compares Impel NeuroPharma and its rivals gross revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Impel NeuroPharma||$670,000.00||-$76.54 million||-0.33|
|Impel NeuroPharma Competitors||$1.83 billion||$238.18 million||-1.72|
Impel NeuroPharma’s rivals have higher revenue and earnings than Impel NeuroPharma. Impel NeuroPharma is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
About Impel NeuroPharma (Get Rating)
Impel NeuroPharma, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for patients suffering from central nervous system disease in the United States. Its lead product candidate is TRUDHESA, an upper nasal formulation of dihydroergotamine for the acute treatment of migraine. The company is also developing INP105, an upper nasal formulation of olanzapine for the acute treatment of agitation and aggression in autism spectrum disorder; and INP107, an upper nasal formulation of carbidopa/levodopa, which has completed Phase IIa clinical trial for the treatment of OFF episodes in Parkinson's disease. Impel NeuroPharma, Inc. was incorporated in 2008 and is headquartered in Seattle, Washington.
Receive News & Ratings for Impel NeuroPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Impel NeuroPharma and related companies with MarketBeat.com's FREE daily email newsletter.